The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session and a presentation by Molly Wynveen discussing survival in Veterans with metastatic hormone-sensitive prostate ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

The understanding of prostate cancer has significantly evolved in the past 15 years. However, many people—including primary care providers—may not be aware of the current guidelines for prostate ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than current tests, according to a U.K.-wide study led by UCL researchers. The ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...